1
|
Fu C, Tong W, Yu L, Miao Y, Wei Q, Yu Z, Chen B, Wei M. When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside? Pharmacol Res 2024; 203:107160. [PMID: 38547937 DOI: 10.1016/j.phrs.2024.107160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/21/2024] [Revised: 03/17/2024] [Accepted: 03/25/2024] [Indexed: 04/30/2024]
Abstract
Immunostimulatory antibody conjugates (ISACs) as a promising new generation of targeted therapeutic antibody-drug conjugates (ADCs), that not only activate innate immunity but also stimulate adaptive immunity, providing a dual therapeutic effect to eliminate tumor cells. However, several ISACs are still in the early stages of clinical development or have already failed. Therefore, it is crucial to design ISACs more effectively to overcome their limitations, including high toxicity, strong immunogenicity, long development time, and poor pharmacokinetics. This review aims to summarize the composition and function of ISACs, incorporating current design considerations and ongoing clinical trials. Additionally, the review delves into the current issues with ISACs and potential solutions, such as adjusting the drug-antibody ratio (DAR) to improve the bioavailability of ISACs. By leveraging the affinity and bioavailability-enhancing properties of bispecific antibodies, the utility between antibodies and immunostimulatory agents can be balanced. Commonly used immunostimulatory agents may induce systemic immune reactions, and BTK (Bruton's tyrosine kinase) inhibitors can regulate immunogenicity. Finally, the concept of grafting ADC's therapeutic principles is simple, but the combination of payload, linker, and targeted functional molecules is not a simple permutation and combination problem. The development of conjugate drugs faces more complex pharmacological and toxicological issues. Standing on the shoulders of ADC, the development and application scenarios of ISAC are endowed with broader space.
Collapse
Affiliation(s)
- Chen Fu
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, PR China; Liaoning Key Laboratory of Molecular Targeted Anti-tumor Drug Development and Evaluation, China Medical University, Shenyang 110122, PR China
| | - Weiwei Tong
- Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang 110122, PR China
| | - Lifeng Yu
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, PR China; Liaoning Key Laboratory of Molecular Targeted Anti-tumor Drug Development and Evaluation, China Medical University, Shenyang 110122, PR China
| | - Yuxi Miao
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, PR China; Liaoning Key Laboratory of Molecular Targeted Anti-tumor Drug Development and Evaluation, China Medical University, Shenyang 110122, PR China
| | - Qian Wei
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, PR China; Liaoning Key Laboratory of Molecular Targeted Anti-tumor Drug Development and Evaluation, China Medical University, Shenyang 110122, PR China
| | - Zhaojin Yu
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, PR China; Liaoning Key Laboratory of Molecular Targeted Anti-tumor Drug Development and Evaluation, China Medical University, Shenyang 110122, PR China.
| | - Bo Chen
- Department of Breast Surgery, The First Hospital of China Medical University, No. 155, Nanjing North Street, Shenyang 110122, PR China.
| | - Minjie Wei
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, PR China; Liaoning Key Laboratory of Molecular Targeted Anti-tumor Drug Development and Evaluation, China Medical University, Shenyang 110122, PR China.
| |
Collapse
|
2
|
Bourgery C, Mendoza DJ, Garnier G, Mouterde LMM, Allais F. Immobilization of Adenosine Derivatives onto Cellulose Nanocrystals via Click Chemistry for Biocatalysis Applications. ACS APPLIED MATERIALS & INTERFACES 2024; 16:11315-11323. [PMID: 38394235 DOI: 10.1021/acsami.3c19025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/25/2024]
Abstract
Adenosine triphosphate (ATP) is a central molecule of organisms and is involved in many biological processes. It is also widely used in biocatalytic processes, especially as a substrate and precursor of many cofactors─such as nicotinamide adenine dinucleotide phosphate (NADP(H)), coenzyme A (CoA), and S-adenosylmethionine (SAM). Despite its great scientific interest and pivotal role, its use in industrial processes is impeded by its prohibitory cost. To overcome this limitation, we developed a greener synthesis of adenosine derivatives and efficiently selectively grafted them onto organic nanoparticles. In this study, cellulose nanocrystals were used as a model combined with click chemistry via a copper-catalyzed azide/alkyne cycloaddition reaction (CuAAC). The grafted adenosine triphosphate derivative fully retains its biocatalytic capability, enabling heterobiocatalysis for modern biochemical processes.
Collapse
Affiliation(s)
- Célestin Bourgery
- URD Agro-Biotechnologies Industrielles (ABI), CEBB, AgroParisTech, Pomacle 51110, France
| | - David Joram Mendoza
- Bioresource Processing Research Institute of Australia (BioPRIA), Department of Chemical and Biological Engineering, Monash University, Clayton, VIC 3800, Australia
| | - Gil Garnier
- URD Agro-Biotechnologies Industrielles (ABI), CEBB, AgroParisTech, Pomacle 51110, France
- Bioresource Processing Research Institute of Australia (BioPRIA), Department of Chemical and Biological Engineering, Monash University, Clayton, VIC 3800, Australia
| | - Louis M M Mouterde
- URD Agro-Biotechnologies Industrielles (ABI), CEBB, AgroParisTech, Pomacle 51110, France
| | - Florent Allais
- URD Agro-Biotechnologies Industrielles (ABI), CEBB, AgroParisTech, Pomacle 51110, France
- Bioresource Processing Research Institute of Australia (BioPRIA), Department of Chemical and Biological Engineering, Monash University, Clayton, VIC 3800, Australia
| |
Collapse
|
3
|
Caceres-Cortes J, Falk B, Mueller L, Dhar TGM. Perspectives on Nuclear Magnetic Resonance Spectroscopy in Drug Discovery Research. J Med Chem 2024; 67:1701-1733. [PMID: 38290426 DOI: 10.1021/acs.jmedchem.3c02389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2024]
Abstract
The drug discovery landscape has undergone a significant transformation over the past decade, owing to research endeavors in a wide range of areas leading to strategies for pursuing new drug targets and the emergence of novel drug modalities. NMR spectroscopy has been a technology of fundamental importance to these research pursuits and has seen its use expanded both within and outside of traditional medicinal chemistry applications. In this perspective, we will present advancement of NMR-derived methods that have facilitated the characterization of small molecules and novel drug modalities including macrocyclic peptides, cyclic dinucleotides, and ligands for protein degradation. We will discuss innovations in NMR spectroscopy at the chemistry and biology interface that have broadened NMR's utility from hit identification through lead optimization activities. We will also discuss the promise of emerging NMR approaches in bridging our understanding and addressing challenges in the pursuit of the therapeutic agents of the future.
Collapse
Affiliation(s)
- Janet Caceres-Cortes
- Synthesis and Enabling Technologies, Small Molecule Drug Discovery, Bristol-Myers Squibb Company, Princeton, New Jersey 08540, United States
| | - Bradley Falk
- Synthesis and Enabling Technologies, Small Molecule Drug Discovery, Bristol-Myers Squibb Company, Princeton, New Jersey 08540, United States
| | - Luciano Mueller
- Synthesis and Enabling Technologies, Small Molecule Drug Discovery, Bristol-Myers Squibb Company, Princeton, New Jersey 08540, United States
| | - T G Murali Dhar
- Discovery Chemistry, Small Molecule Drug Discovery, Bristol-Myers Squibb Company, Princeton, New Jersey 085401, United States
| |
Collapse
|
4
|
Liu ZQ. Is it still worth renewing nucleoside anticancer drugs nowadays? Eur J Med Chem 2024; 264:115987. [PMID: 38056297 DOI: 10.1016/j.ejmech.2023.115987] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2023] [Revised: 11/11/2023] [Accepted: 11/19/2023] [Indexed: 12/08/2023]
Abstract
Nucleoside has situated the convergence point in the discovery of novel drugs for decades, and a large number of nucleoside derivatives have been constructed for screening novel pharmacological properties at various experimental platforms. Notably, nearly 20 nucleosides are approved to be used in the clinic treatment of various cancers. Nevertheless, the blossom of synthetic nucleoside analogs in comparison with the scarcity of nucleoside anticancer drugs leads to a question: Is it still worth insisting on the screening of novel anticancer drugs from nucleoside derivatives? Hence, this review attempts to emphasize the importance of nucleoside analogs in the discovery of novel anticancer drugs. Firstly, we introduce the metabolic procedures of nucleoside anticancer drug (such as 5-fluorouracil) and summarize the designing of novel nucleoside anticancer candidates based on clinically used nucleoside anticancer drugs (such as gemcitabine). Furthermore, we collect anticancer properties of some recently synthesized nucleoside analogs, aiming at emphasizing the availability of nucleoside analogs in the discovery of anticancer drugs. Finally, a variety of synthetic strategies including the linkage of sugar moiety with nucleobase scaffold, modifications on the sugar moiety, and variations on the nucleobase structure are collected to exhibit the abundant protocols in the achievement of nucleoside analogs. Taken the above discussions collectively, nucleoside still advantages for the finding of novel anticancer drugs because of the clearly metabolic procedures, successfully clinic applications, and abundantly synthetic routines.
Collapse
Affiliation(s)
- Zai-Qun Liu
- Department of Organic Chemistry, College of Chemistry, Jilin University, Changchun, 130021, People's Republic of China.
| |
Collapse
|
5
|
Jekle A, Thatikonda SK, Jaisinghani R, Ren S, Kinkade A, Stevens SK, Stoycheva A, Rajwanshi VK, Williams C, Deval J, Mukherjee S, Zhang Q, Chanda S, Smith DB, Blatt LM, Symons JA, Gonzalvez F, Beigelman L. Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models. Int J Mol Sci 2023; 24:16274. [PMID: 38003463 PMCID: PMC10671074 DOI: 10.3390/ijms242216274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Revised: 11/08/2023] [Accepted: 11/10/2023] [Indexed: 11/26/2023] Open
Abstract
Stimulator of interferon genes (STING) agonists have shown potent anti-tumor efficacy in various mouse tumor models and have the potential to overcome resistance to immune checkpoint inhibitors (ICI) by linking the innate and acquired immune systems. First-generation STING agonists are administered intratumorally; however, a systemic delivery route would greatly expand the clinical use of STING agonists. Biochemical and cell-based experiments, as well as syngeneic mouse efficacy models, were used to demonstrate the anti-tumoral activity of ALG-031048, a novel STING agonist. In vitro, ALG-031048 is highly stable in plasma and liver microsomes and is resistant to degradation via phosphodiesterases. The high stability in biological matrices translated to good cellular potency in a HEK 293 STING R232 reporter assay, efficient activation and maturation of primary human dendritic cells and monocytes, as well as long-lasting, antigen-specific anti-tumor activity in up to 90% of animals in the CT26 mouse colon carcinoma model. Significant reductions in tumor growth were observed in two syngeneic mouse tumor models following subcutaneous administration. Combinations of ALG-031048 and ICIs further enhanced the in vivo anti-tumor activity. This initial demonstration of anti-tumor activity after systemic administration of ALG-031048 warrants further investigation, while the combination of systemically administered ALG-031048 with ICIs offers an attractive approach to overcome key limitations of ICIs in the clinic.
Collapse
Affiliation(s)
- Andreas Jekle
- Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA (S.K.S.); (A.S.); (V.K.R.); (S.C.); (D.B.S.); (L.M.B.); (J.A.S.); (L.B.)
| | - Santosh Kumar Thatikonda
- Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA (S.K.S.); (A.S.); (V.K.R.); (S.C.); (D.B.S.); (L.M.B.); (J.A.S.); (L.B.)
| | - Ruchika Jaisinghani
- Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA (S.K.S.); (A.S.); (V.K.R.); (S.C.); (D.B.S.); (L.M.B.); (J.A.S.); (L.B.)
| | - Suping Ren
- Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA (S.K.S.); (A.S.); (V.K.R.); (S.C.); (D.B.S.); (L.M.B.); (J.A.S.); (L.B.)
| | - April Kinkade
- Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA (S.K.S.); (A.S.); (V.K.R.); (S.C.); (D.B.S.); (L.M.B.); (J.A.S.); (L.B.)
| | - Sarah K. Stevens
- Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA (S.K.S.); (A.S.); (V.K.R.); (S.C.); (D.B.S.); (L.M.B.); (J.A.S.); (L.B.)
| | - Antitsa Stoycheva
- Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA (S.K.S.); (A.S.); (V.K.R.); (S.C.); (D.B.S.); (L.M.B.); (J.A.S.); (L.B.)
| | - Vivek K. Rajwanshi
- Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA (S.K.S.); (A.S.); (V.K.R.); (S.C.); (D.B.S.); (L.M.B.); (J.A.S.); (L.B.)
| | - Caroline Williams
- Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA (S.K.S.); (A.S.); (V.K.R.); (S.C.); (D.B.S.); (L.M.B.); (J.A.S.); (L.B.)
| | - Jerome Deval
- Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA (S.K.S.); (A.S.); (V.K.R.); (S.C.); (D.B.S.); (L.M.B.); (J.A.S.); (L.B.)
| | - Sucheta Mukherjee
- Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA (S.K.S.); (A.S.); (V.K.R.); (S.C.); (D.B.S.); (L.M.B.); (J.A.S.); (L.B.)
| | - Qingling Zhang
- Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA (S.K.S.); (A.S.); (V.K.R.); (S.C.); (D.B.S.); (L.M.B.); (J.A.S.); (L.B.)
| | - Sushmita Chanda
- Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA (S.K.S.); (A.S.); (V.K.R.); (S.C.); (D.B.S.); (L.M.B.); (J.A.S.); (L.B.)
| | - David B. Smith
- Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA (S.K.S.); (A.S.); (V.K.R.); (S.C.); (D.B.S.); (L.M.B.); (J.A.S.); (L.B.)
| | - Lawrence M. Blatt
- Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA (S.K.S.); (A.S.); (V.K.R.); (S.C.); (D.B.S.); (L.M.B.); (J.A.S.); (L.B.)
| | - Julian A. Symons
- Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA (S.K.S.); (A.S.); (V.K.R.); (S.C.); (D.B.S.); (L.M.B.); (J.A.S.); (L.B.)
| | | | - Leonid Beigelman
- Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA (S.K.S.); (A.S.); (V.K.R.); (S.C.); (D.B.S.); (L.M.B.); (J.A.S.); (L.B.)
| |
Collapse
|
6
|
Casamajo A, Yu Y, Schnepel C, Morrill C, Barker R, Levy CW, Finnigan J, Spelling V, Westerlund K, Petchey M, Sheppard RJ, Lewis RJ, Falcioni F, Hayes MA, Turner NJ. Biocatalysis in Drug Design: Engineered Reductive Aminases (RedAms) Are Used to Access Chiral Building Blocks with Multiple Stereocenters. J Am Chem Soc 2023; 145:22041-22046. [PMID: 37782882 PMCID: PMC10571080 DOI: 10.1021/jacs.3c07010] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Indexed: 10/04/2023]
Abstract
Novel building blocks are in constant demand during the search for innovative bioactive small molecule therapeutics by enabling the construction of structure-activity-property-toxicology relationships. Complex chiral molecules containing multiple stereocenters are an important component in compound library expansion but can be difficult to access by traditional organic synthesis. Herein, we report a biocatalytic process to access a specific diastereomer of a chiral amine building block used in drug discovery. A reductive aminase (RedAm) was engineered following a structure-guided mutagenesis strategy to produce the desired isomer. The engineered RedAm (IR-09 W204R) was able to generate the (S,S,S)-isomer 3 in 45% conversion and 95% ee from the racemic ketone 2. Subsequent palladium-catalyzed deallylation of 3 yielded the target primary amine 4 in a 73% yield. This engineered biocatalyst was used at preparative scale and represents a potential starting point for further engineering and process development.
Collapse
Affiliation(s)
- Arnau
Rué Casamajo
- Department
of Chemistry, University of Manchester, Manchester Institute of Biotechnology, 131 Princess Street, Manchester M1 7DN, United
Kingdom
| | - Yuqi Yu
- Department
of Chemistry, University of Manchester, Manchester Institute of Biotechnology, 131 Princess Street, Manchester M1 7DN, United
Kingdom
| | - Christian Schnepel
- School
of Engineering Sciences in Chemistry, Biotechnology and Health, Department
of Industrial Biotechnology, KTH Royal Institute of Technology, AlbaNova University Center, 11421 Stockholm, Sweden
| | - Charlotte Morrill
- Department
of Chemistry, University of Manchester, Manchester Institute of Biotechnology, 131 Princess Street, Manchester M1 7DN, United
Kingdom
| | - Rhys Barker
- Department
of Chemistry, University of Manchester, Manchester Institute of Biotechnology, 131 Princess Street, Manchester M1 7DN, United
Kingdom
| | - Colin W. Levy
- Department
of Chemistry, University of Manchester, Manchester Institute of Biotechnology, 131 Princess Street, Manchester M1 7DN, United
Kingdom
| | - James Finnigan
- Prozomix
Ltd, Building 4, West
End Ind. Estate, Haltwhistle NE49 9HA, United Kingdom
| | - Victor Spelling
- Early
Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals
R&D, AstraZeneca, Mölndal, 431 50 Gothenburg, Sweden
| | - Kristina Westerlund
- Medicinal
Chemistry, Research and Early Development; Cardiovascular, Renal and
Metabolism, Biopharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 431 50 Gothenburg Sweden
| | - Mark Petchey
- Compound
Synthesis and Management, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Mölndal, 431 50 Gothenburg, Sweden
| | - Robert J. Sheppard
- Medicinal
Chemistry, Research and Early Development; Cardiovascular, Renal and
Metabolism, Biopharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal, 431 50 Gothenburg Sweden
| | - Richard J. Lewis
- Department
of Medicinal Chemistry, Research and Early Development, Respiratory
and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, 43183 Mölndal, Sweden
| | - Francesco Falcioni
- Early
Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals
R&D, AstraZeneca, CB21 6GP Cambridge, United Kingdom
| | - Martin A. Hayes
- Compound
Synthesis and Management, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Mölndal, 431 50 Gothenburg, Sweden
| | - Nicholas J. Turner
- Department
of Chemistry, University of Manchester, Manchester Institute of Biotechnology, 131 Princess Street, Manchester M1 7DN, United
Kingdom
| |
Collapse
|
7
|
France SP, Lewis RD, Martinez CA. The Evolving Nature of Biocatalysis in Pharmaceutical Research and Development. JACS AU 2023; 3:715-735. [PMID: 37006753 PMCID: PMC10052283 DOI: 10.1021/jacsau.2c00712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/31/2022] [Revised: 02/13/2023] [Accepted: 02/13/2023] [Indexed: 06/19/2023]
Abstract
Biocatalysis is a highly valued enabling technology for pharmaceutical research and development as it can unlock synthetic routes to complex chiral motifs with unparalleled selectivity and efficiency. This perspective aims to review recent advances in the pharmaceutical implementation of biocatalysis across early and late-stage development with a focus on the implementation of processes for preparative-scale syntheses.
Collapse
|
8
|
Neel AJ, Liu Z, Benkovics T, Wang L, Rummelt SM, Johnson HC, Belyk KM, Xu F, Chung CK, Lamberto DJ, Cohen RD, Axnanda S, Dance ZEX. Development of a Kilogram-Scale Synthesis of a Key Ulevostinag Subunit Part II: An Electrophilic Approach to Fluorinated Nucleosides. Org Process Res Dev 2023. [DOI: 10.1021/acs.oprd.2c00395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/09/2023]
Affiliation(s)
- Andrew J. Neel
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Zhuqing Liu
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Tamas Benkovics
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Lu Wang
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Stephan M. Rummelt
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Heather C. Johnson
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Kevin M. Belyk
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Feng Xu
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Cheol K. Chung
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - David J. Lamberto
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Ryan D. Cohen
- Analytical Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Stephanus Axnanda
- Analytical Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Zachary E. X. Dance
- Analytical Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| |
Collapse
|
9
|
Turnbull BWH, Peng F, Neel AJ, Benkovics T, Liu Z, Chung CK, Song ZJ, Tan L, Emerson KM, Xiao C, Zhang Y, Sherry BD. Development of a Kilogram-Scale Synthesis of a Key Ulevostinag Subunit Part I: Accessing a Keto-Nucleoside Intermediate from Guanosine. Org Process Res Dev 2023. [DOI: 10.1021/acs.oprd.2c00397] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/09/2023]
Affiliation(s)
- Ben W. H. Turnbull
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Feng Peng
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Andrew J. Neel
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Tamas Benkovics
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Zhuqing Liu
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Cheol K. Chung
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Zhiguo Jake Song
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Lushi Tan
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Khateeta M. Emerson
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Chengqian Xiao
- Shanghai SynTheAll Pharmaceutical Co., Ltd., Shanghai 201507, China
| | - Yi Zhang
- Shanghai SynTheAll Pharmaceutical Co., Ltd., Shanghai 201507, China
| | - Benjamin D. Sherry
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| |
Collapse
|
10
|
Cohen B, Lehnherr D, Sezen-Edmonds M, Forstater JH, Frederick MO, Deng L, Ferretti AC, Harper K, Diwan M. Emerging Reaction Technologies in Pharmaceutical Development: Challenges and Opportunities in Electrochemistry, Photochemistry, and Biocatalysis. Chem Eng Res Des 2023. [DOI: 10.1016/j.cherd.2023.02.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
|
11
|
Abstract
The discovery of cGAMP in 2012 filled an important gap in our understanding of innate immune signaling. It has been known for over a century that DNA can induce immune responses, but the underlying mechanism was not clear. With the identification of STING as a key player in interferon induction, the DNA detector that activates STING was the last missing link in TBK1-IRF3 signaling. Somewhat unexpectedly, it turns out that nature relays the DNA danger signal through a small molecule. cGAMP is a cyclic dinucleotide produced from cyclodimerization of ATP and GTP upon detection of cytosolic DNA by cGAS, a previously uncharacterized protein, to promote the assembly of the STING signalosome. This article covers a personal account of the discovery of cGAMP, a short history of the relevant nucleotide chemistry, and a summary of the latest development in this field of research in chemistry. It is the author's hope that, with a historic perspective, the readers can better appreciate the synergy between chemistry and biology in drug development.
Collapse
Affiliation(s)
- Chuo Chen
- Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9038, USA
| |
Collapse
|
12
|
Advances in the Synthesis and Analysis of Biologically Active Phosphometabolites. Int J Mol Sci 2023; 24:ijms24043150. [PMID: 36834560 PMCID: PMC9961378 DOI: 10.3390/ijms24043150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Revised: 02/01/2023] [Accepted: 02/01/2023] [Indexed: 02/09/2023] Open
Abstract
Phosphorus-containing metabolites cover a large molecular diversity and represent an important domain of small molecules which are highly relevant for life and represent essential interfaces between biology and chemistry, between the biological and abiotic world. The large but not unlimited amount of phosphate minerals on our planet is a key resource for living organisms on our planet, while the accumulation of phosphorus-containing waste is associated with negative effects on ecosystems. Therefore, resource-efficient and circular processes receive increasing attention from different perspectives, from local and regional levels to national and global levels. The molecular and sustainability aspects of a global phosphorus cycle have become of much interest for addressing the phosphorus biochemical flow as a high-risk planetary boundary. Knowledge of balancing the natural phosphorus cycle and the further elucidation of metabolic pathways involving phosphorus is crucial. This requires not only the development of effective new methods for practical discovery, identification, and high-information content analysis, but also for practical synthesis of phosphorus-containing metabolites, for example as standards, as substrates or products of enzymatic reactions, or for discovering novel biological functions. The purpose of this article is to review the advances which have been achieved in the synthesis and analysis of phosphorus-containing metabolites which are biologically active.
Collapse
|
13
|
Chen R, Liu M, Jiang Q, Meng X, Wei J. The cyclic guanosine monophosphate synthase-stimulator of interferon genes pathway as a potential target for tumor immunotherapy. Front Immunol 2023; 14:1121603. [PMID: 37153627 PMCID: PMC10160662 DOI: 10.3389/fimmu.2023.1121603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Accepted: 04/07/2023] [Indexed: 05/10/2023] Open
Abstract
Cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) synthase (cGAS) detects infections or tissue damage by binding to microbial or self-DNA in the cytoplasm. Upon binding DNA, cGAS produces cGAMP that binds to and activates the adaptor protein stimulator of interferon genes (STING), which then activates the kinases IKK and TBK1 to induce the secretion of interferons and other cytokines. Recently, a series of studies demonstrated that the cGAS-STING pathway, a vital component of host innate immunity, might play an important role in anticancer immunity, though its mechanism remains to be elucidated. In this review, we highlight the latest understanding of the cGAS-STING pathway in tumor development and the advances in combination therapy of STING agonists and immunotherapy.
Collapse
Affiliation(s)
- Rui Chen
- Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
| | - Mingxia Liu
- Department of Biochemistry and Molecular Biology, Department of Immunology, School of Basic Medical Science, Tianjin Medical University, Tianjin, China
| | - Quanhong Jiang
- Advanced Medical Research Institute, Meili Lake Translational Research Park, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
| | - Xiangbo Meng
- Advanced Medical Research Institute, Meili Lake Translational Research Park, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
- *Correspondence: Junmin Wei, ; Xiangbo Meng,
| | - Junmin Wei
- Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
- *Correspondence: Junmin Wei, ; Xiangbo Meng,
| |
Collapse
|
14
|
Winston MS, Poirier M, Liu Z, Peng F, Humphrey GR, McIntosh JA, Reibarkh M, Wang F, Guetschow ED, Castro S, Hoyt E, Lamberto DJ, Sirk K. pH-Switchable Phase-Transfer Agents for Host Cell Protein Rejection in the Cascaded Biocatalytic Synthesis of an Active Pharmaceutical Ingredient. Org Process Res Dev 2022. [DOI: 10.1021/acs.oprd.2c00327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Matthew S. Winston
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Marc Poirier
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Zhijian Liu
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Feng Peng
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Guy R. Humphrey
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - John A. McIntosh
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Mikhail Reibarkh
- Analytical Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Fengqiang Wang
- Analytical Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Erik D. Guetschow
- Analytical Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Steve Castro
- Analytical Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Erik Hoyt
- Analytical Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - David J. Lamberto
- Chemical Engineering Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Kevin Sirk
- Chemical Engineering Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| |
Collapse
|
15
|
Ruck RT, Strotman NA, Krska SW. The Catalysis Laboratory at Merck: 20 Years of Catalyzing Innovation. ACS Catal 2022. [DOI: 10.1021/acscatal.2c05159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Rebecca T. Ruck
- Department of Process Research & Development, Merck & Co., Inc., Rahway, New Jersey07065, United States
| | - Neil A. Strotman
- Department of Pharmaceutical Sciences & Clinical Supplies, Merck & Co., Inc., Rahway, New Jersey07065, United States
| | - Shane W. Krska
- Chemistry Capabilities Accelerating Therapeutics, Merck & Co., Inc., Kenilworth, New Jersey07033, United States
| |
Collapse
|
16
|
Industrial potential of the enzymatic synthesis of nucleoside analogs: existing challenges and perspectives. Curr Opin Biotechnol 2022; 78:102829. [PMID: 36332344 DOI: 10.1016/j.copbio.2022.102829] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2022] [Revised: 09/16/2022] [Accepted: 09/30/2022] [Indexed: 12/14/2022]
Abstract
Nucleoside phosphorylases have progressed from an enzymatic curiosity to a viable synthetic tool. However, despite the recent advances in nucleoside phosphorylase-catalyzed nucleoside synthesis, the widespread application of these enzymes in industrial processes is still lacking. We attribute this gap to three key challenges, which are outlined in this short review. To address these persistent obstacles, we believe that biocatalytic nucleoside synthesis needs to embrace interdisciplinary partnerships with the fields of organic chemistry, process engineering, and flow chemistry.
Collapse
|
17
|
Neel AJ, Turnbull BWH, Carson WP, Benkovics T, Chung CK, Johnson HC, Liu Z, Peng F, Rummelt SM, Song ZJ, Tan L, Wang L, Xu F. A Unified Strategy to Fluorinated Nucleoside Analogues Via an Electrophilic Manifold. Org Lett 2022; 24:7701-7706. [PMID: 36227065 DOI: 10.1021/acs.orglett.2c03367] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Herein, we present a strategy for the preparation of 3'-fluorinated nucleoside analogues via the aminocatalytic, electrophilic fluorination of readily accessible and bench-stable 2'-ketonucleosides. Initially developed to facilitate the manufacture of 3'-fluoroguanosine (3'-FG)─a substructure of anticancer therapeutic MK-1454─this strategy has been extended to the synthesis of a variety of 3'-fluoronucleosides. Finally, we demonstrate the utility of the 2'-ketonucleoside synthon as a platform for further diversification and suggest that this methodology should be broadly applicable to the discovery of novel nucleoside analogues.
Collapse
Affiliation(s)
- Andrew J Neel
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Ben W H Turnbull
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - William P Carson
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Tamas Benkovics
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Cheol K Chung
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Heather C Johnson
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Zhuqing Liu
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Feng Peng
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Stephan M Rummelt
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Zhiguo Jake Song
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Lushi Tan
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Lu Wang
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Feng Xu
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| |
Collapse
|
18
|
Lv J, Xing C, Chen Y, Bian H, Lv N, Wang Z, Liu M, Su L. The STING in Non-Alcoholic Fatty Liver Diseases: Potential Therapeutic Targets in Inflammation-Carcinogenesis Pathway. Pharmaceuticals (Basel) 2022; 15:1241. [PMID: 36297353 PMCID: PMC9611148 DOI: 10.3390/ph15101241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2022] [Revised: 09/27/2022] [Accepted: 09/28/2022] [Indexed: 11/25/2022] Open
Abstract
Non-alcoholic fatty liver disease (NAFLD), an important chronic disease, is one of the major causes of high mortality and creates a substantial financial burden worldwide. The various immune cells in the liver, including macrophages, NK cells, dendritic cells, and the neutrophils involved in the innate immune response, trigger inflammation after recognizing the damage signaled from infection or injured cells and tissues. The stimulator of interferon genes (STING) is a critical molecule that binds to the cyclic dinucleotides (CDNs) generated by the cyclic GMP-AMP synthase (cGAS) to initiate the innate immune response against infection. Previous studies have demonstrated that the cGAS-STING pathway plays a critical role in inflammatory, auto-immune, and anti-viral immune responses. Recently, studies have focused on the role of STING in liver diseases, the results implying that alterations in its activity may be involved in the pathogenesis of liver disorders. Here, we summarize the function of STING in the development of NAFLD and present the current inhibitors and agonists targeting STING.
Collapse
Affiliation(s)
- Juan Lv
- Institute of Translational Medicine, Shanghai University, Shanghai 200444, China
| | - Chunlei Xing
- Institute of Translational Medicine, Shanghai University, Shanghai 200444, China
| | - Yuhong Chen
- Institute of Translational Medicine, Shanghai University, Shanghai 200444, China
- School of Pharmacy, Bengbu Medical College, Bengbu 233030, China
| | - Huihui Bian
- Institute of Translational Medicine, Shanghai University, Shanghai 200444, China
| | - Nanning Lv
- Lianyungang Second People’s Hospital, Lianyungang 222002, China
| | - Zhibin Wang
- Department of Critical Care Medicine, School of Anesthesiology, Naval Medical University, Shanghai 200020, China
- School of Pharmacy, Naval Medical University, Shanghai 200433, China
| | - Mingming Liu
- Lianyungang Second People’s Hospital, Lianyungang 222002, China
| | - Li Su
- Institute of Translational Medicine, Shanghai University, Shanghai 200444, China
| |
Collapse
|
19
|
Tian X, Xu F, Zhu Q, Feng Z, Dai W, Zhou Y, You QD, Xu X. Medicinal chemistry perspective on cGAS-STING signaling pathway with small molecule inhibitors. Eur J Med Chem 2022; 244:114791. [DOI: 10.1016/j.ejmech.2022.114791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2022] [Revised: 09/18/2022] [Accepted: 09/20/2022] [Indexed: 11/04/2022]
|
20
|
Maligres PE, Peng F, Calabria R, Campeau LC, Chen W, Dormer PG, Green M, He CQ, Hyde AM, Klapars A, Larsen MU, Limanto J, Liu G, Liu Y, Moment A, Nowak T, Ruck RT, Shevlin M, Song ZJ, Tan L, Tong W, Waldman JH, Ye H, Zhao R, Zhou G, Zompa MA, Zultanski SL. Manufacturing Process Development for Uprifosbuvir (MK-3682): A Green and Sustainable Process for Preparing Penultimate 2′-Deoxy-α-2′-Chloro-β-2′-Methyluridine. Org Process Res Dev 2022. [DOI: 10.1021/acs.oprd.2c00191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Peter E. Maligres
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Feng Peng
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Ralph Calabria
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Louis-Charles Campeau
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Wenyong Chen
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Peter G. Dormer
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Meredith Green
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Cyndi Qixin He
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Alan M. Hyde
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Artis Klapars
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Mona Utne Larsen
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - John Limanto
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Guiquan Liu
- Shanghai SynTheAll Pharmaceutical Co. Ltd., 9 Yuegong Road, Jinshan District, Shanghai 201507, China
| | - Yizhou Liu
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Aaron Moment
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Timothy Nowak
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Rebecca T. Ruck
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Michael Shevlin
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Zhiguo Jake Song
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Lushi Tan
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Weidong Tong
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Jacob H. Waldman
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Honglin Ye
- Shanghai SynTheAll Pharmaceutical Co. Ltd., 9 Yuegong Road, Jinshan District, Shanghai 201507, China
| | - Ralph Zhao
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - George Zhou
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Michael A. Zompa
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Susan L. Zultanski
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| |
Collapse
|
21
|
Chemo-enzymatic synthesis of natural products and their analogs. Curr Opin Biotechnol 2022; 77:102759. [PMID: 35908314 DOI: 10.1016/j.copbio.2022.102759] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2022] [Revised: 06/21/2022] [Accepted: 06/24/2022] [Indexed: 11/20/2022]
Abstract
Enzymes continue to gain recognition as valuable tools in synthetic chemistry as they enable transformations, which elude conventional organochemical approaches. As such, the progressing expansion of the biocatalytic arsenal has introduced unprecedented opportunities for new synthetic strategies and retrosynthetic disconnections. As a result, enzymes have found a solid foothold in modern natural product synthesis for applications ranging from the generation of early chiral synthons to endgame transformations, convergent synthesis, and cascade reactions for the rapid construction of molecular complexity. As a primer to the state-of-the-art concerning strategic uses of enzymes in natural product synthesis and the underlying concepts, this review highlights selected recent literature examples, which make a strong case for the admission of enzymatic methodologies into the standard repertoire for complex small-molecule synthesis.
Collapse
|
22
|
Wohlgemuth R, Littlechild J. Complexity reduction and opportunities in the design, integration and intensification of biocatalytic processes for metabolite synthesis. Front Bioeng Biotechnol 2022; 10:958606. [PMID: 35935499 PMCID: PMC9355135 DOI: 10.3389/fbioe.2022.958606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2022] [Accepted: 06/28/2022] [Indexed: 11/13/2022] Open
Abstract
The biosynthesis of metabolites from available starting materials is becoming an ever important area due to the increasing demands within the life science research area. Access to metabolites is making essential contributions to analytical, diagnostic, therapeutic and different industrial applications. These molecules can be synthesized by the enzymes of biological systems under sustainable process conditions. The facile synthetic access to the metabolite and metabolite-like molecular space is of fundamental importance. The increasing knowledge within molecular biology, enzyme discovery and production together with their biochemical and structural properties offers excellent opportunities for using modular cell-free biocatalytic systems. This reduces the complexity of synthesizing metabolites using biological whole-cell approaches or by classical chemical synthesis. A systems biocatalysis approach can provide a wealth of optimized enzymes for the biosynthesis of already identified and new metabolite molecules.
Collapse
Affiliation(s)
- Roland Wohlgemuth
- Institute of Molecular and Industrial Biotechnology, Lodz University of Technology, Lodz, Poland
- Swiss Coordination Committee for Biotechnology, Zurich, Switzerland
- *Correspondence: Roland Wohlgemuth, ; Jennifer Littlechild,
| | - Jennifer Littlechild
- Henry Wellcome Building for Biocatalysis, Biosciences, University of Exeter, Exeter, United Kingdom
- *Correspondence: Roland Wohlgemuth, ; Jennifer Littlechild,
| |
Collapse
|
23
|
Pirnot MT, Mao E, Lam YH, Limanto J, Cohen RD, Chung CK, Phillips EM. A Diastereoselective Method for the Construction of syn-2'-Deoxy-2'-fluoronucleosides. Org Lett 2022; 24:4860-4864. [PMID: 35793545 DOI: 10.1021/acs.orglett.2c01561] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A general and diastereoselective fluorination/glycosylation strategy for the synthesis of 2'-fluorinated nucleosides has been developed. Electrophilic fluorination of a glycal with NFSI provided the 1',2'-difunctionalized furanoside intermediate with high diastereoselectivity. The TBS-protected 2'-deoxyfluorosulfonimide sugar was prepared on an 80 g scale and isolated as a crystalline, bench-stable single diastereomer. This intermediate was found to undergo a subsequent glycosylation reaction with a variety of heteroaryl nucleophiles with generally good diastereoselectivities.
Collapse
Affiliation(s)
- Michael T Pirnot
- Department of Process Research and Development, Merck Research Laboratories, 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Edna Mao
- Department of Process Research and Development, Merck Research Laboratories, 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Yu-Hong Lam
- Department of Computational and Structural Chemistry, Merck Research Laboratories, 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - John Limanto
- Department of Process Research and Development, Merck Research Laboratories, 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Ryan D Cohen
- Department of Process Research and Development, Merck Research Laboratories, 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Cheol K Chung
- Department of Process Research and Development, Merck Research Laboratories, 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Eric M Phillips
- Department of Process Research and Development, Merck Research Laboratories, 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| |
Collapse
|
24
|
Tremblay T, Alcée JB, Giguère D. Protecting-group-free synthesis of clevudine ( l-FMAU), a treatment of the hepatitis B virus. Org Biomol Chem 2022; 20:8859-8863. [DOI: 10.1039/d2ob01814d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
A new strategy for the synthesis of unnatural 2′-deoxy-2′-fluoro-l-nucleoside is described.
Collapse
Affiliation(s)
- Thomas Tremblay
- Département de Chimie, 1045 av. De la Médecine, Université Laval, Québec City, Qc, Canada G1V 0A6
| | - Jessica B. Alcée
- Département de Chimie, 1045 av. De la Médecine, Université Laval, Québec City, Qc, Canada G1V 0A6
| | - Denis Giguère
- Département de Chimie, 1045 av. De la Médecine, Université Laval, Québec City, Qc, Canada G1V 0A6
| |
Collapse
|